MA45890B2 - Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes - Google Patents

Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Info

Publication number
MA45890B2
MA45890B2 MA45890A MA45890A MA45890B2 MA 45890 B2 MA45890 B2 MA 45890B2 MA 45890 A MA45890 A MA 45890A MA 45890 A MA45890 A MA 45890A MA 45890 B2 MA45890 B2 MA 45890B2
Authority
MA
Morocco
Prior art keywords
patient
pharmaceutical composition
opioid addiction
composition
preventing opioid
Prior art date
Application number
MA45890A
Other languages
English (en)
French (fr)
Other versions
MA45890A1 (fr
Inventor
Catherine Stehman-Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45890A1 publication Critical patent/MA45890A1/fr
Publication of MA45890B2 publication Critical patent/MA45890B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA45890A 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes MA45890B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (2)

Publication Number Publication Date
MA45890A1 MA45890A1 (fr) 2020-02-28
MA45890B2 true MA45890B2 (fr) 2022-10-31

Family

ID=60766150

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45890A MA45890B2 (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046951A MA46951A (fr) 2016-11-29 2017-11-28 Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes

Country Status (18)

Country Link
US (2) US10736961B2 (enExample)
EP (1) EP3548082B1 (enExample)
JP (1) JP7071975B2 (enExample)
KR (1) KR20190090820A (enExample)
CN (1) CN110072549A (enExample)
AU (1) AU2017366870B2 (enExample)
BR (1) BR112019010331A2 (enExample)
CA (1) CA3045116A1 (enExample)
CL (1) CL2019001385A1 (enExample)
CO (1) CO2019005247A2 (enExample)
EA (1) EA201991283A9 (enExample)
IL (1) IL266640B (enExample)
MA (2) MA45890B2 (enExample)
MX (1) MX2019006013A (enExample)
MY (1) MY200701A (enExample)
PH (1) PH12019501087A1 (enExample)
WO (1) WO2018102294A1 (enExample)
ZA (1) ZA201902967B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
EP4514849A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7988967B2 (en) * 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
PH12013500672A1 (en) 2010-10-06 2013-06-03 Regeneron Pharma Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies

Also Published As

Publication number Publication date
MA46951A (fr) 2019-10-09
EA201991283A1 (ru) 2019-09-30
JP7071975B2 (ja) 2022-05-19
WO2018102294A1 (en) 2018-06-07
CO2019005247A2 (es) 2019-05-31
EP3548082B1 (en) 2024-05-15
US10736961B2 (en) 2020-08-11
AU2017366870A1 (en) 2019-06-06
AU2017366870B2 (en) 2024-09-19
IL266640B (en) 2022-09-01
US11491222B2 (en) 2022-11-08
BR112019010331A2 (pt) 2019-10-22
MY200701A (en) 2024-01-11
EP3548082A1 (en) 2019-10-09
EA201991283A9 (ru) 2019-11-27
MX2019006013A (es) 2019-10-14
PH12019501087A1 (en) 2019-08-19
MA45890A1 (fr) 2020-02-28
CN110072549A (zh) 2019-07-30
ZA201902967B (en) 2024-10-30
CL2019001385A1 (es) 2019-07-26
US20210060159A1 (en) 2021-03-04
IL266640A (en) 2019-07-31
JP2019535716A (ja) 2019-12-12
KR20190090820A (ko) 2019-08-02
US20180147280A1 (en) 2018-05-31
CA3045116A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
Kasperkiewicz et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu'inhibiteurs selectifs de la voie du ngf
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
MA52962B1 (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MA27952A1 (fr) Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
CR20210492A (es) ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
MA33387B1 (fr) Polypeptides et procede de traitement
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
AR083819A1 (es) UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
MA45890B2 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MA38161A1 (fr) Anticorps anti-bmp-6
FR3081090B1 (fr) Probiotique pour volaille
Strnad et al. Hepcidin is an antibacterial, stress-inducible peptide of the biliary system
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2